SCHEMBL3120845

SCHEMBL3120845

CCNCCc1ccc(O)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 1/20 0.63
SIGMAR1 Q99720 1/20 0.63
KDM4E B2RXH2 2/20 0.55
F13A1 P00488 1/20 0.55
ESR1 P03372 3/20 0.54
ESR2 Q92731 1/20 0.54
SLC6A2 P23975 3/20 0.50
SLC6A4 P31645 3/20 0.50
SLC6A3 Q01959 3/20 0.50
ADRA2A P08913 2/20 0.50
ADORA3 P0DMS8 2/20 0.50
TACR2 P21452 2/20 0.50
ADRB3 P13945 2/20 0.50
LMNA P02545 2/20 0.50
HIF1A Q16665 2/20 0.50
OPRK1 P41145 2/20 0.50
ALDH1A1 P00352 1/20 0.50
SHBG P04278 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11486199 0.88 ESR1 (0.57) TMEM97SIGMAR1KDM4EF13A1ESR1
SCHEMBL7381628 0.86 TMEM97 (0.67) TMEM97SIGMAR1KDM4EF13A1ESR1
SCHEMBL7386235 0.85 SIGMAR1 (0.61) TMEM97SIGMAR1KDM4EF13A1ESR1
SCHEMBL31344794 0.83 L3MBTL1 (0.43) TMEM97SIGMAR1KDM4EF13A1ADRB2
SCHEMBL7379754 0.82 ESR1 (0.60) TMEM97SIGMAR1KDM4EF13A1ESR1
SCHEMBL27755949 0.80 SIGMAR1 (0.68) TMEM97SIGMAR1KDM4EF13A1ESR1
SCHEMBL17922520 0.80 TAAR1 (0.59) TMEM97SIGMAR1KDM4ELMNAHIF1A
SCHEMBL13533648 0.80 CA12 (0.50) SIGMAR1ALDH1A1CHRM2CHRM1CHRM3
Bromide SCHEMBL11269859 0.80 SIGMAR1 (0.42) TMEM97SIGMAR1KDM4EF13A1SLC6A2
SCHEMBL28115515 0.79 SIGMAR1 (0.59) TMEM97SIGMAR1KDM4EF13A1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1990002829-A1 ELECTROPOLYMER COATED MICROELECTRODES WOLLONGONG UNIADVICE LIMITED (AU) 1990-03-22 WO claimed
US-11548870-B2 Compounds useful as inhibitors of helios protein BRISTOL-MYERS SQUIBB COMPANY (US) 2023-01-10 US disclosed
WO-2021101919-A1 COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN BRISTOL-MYERS SQUIBB COMPANY (US) 2021-05-27 WO disclosed
US-20210147383-A1 COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN BRISTOL-MYERS SQUIBB COMPANY 2021-05-20 US disclosed
WO-2020037251-A1 BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS G1 THERAPEUTICS, INC. (US) 2020-02-20 WO disclosed
WO-2017049383-A1 LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME CYCLENIUM PHARMA INC. (CA) 2017-03-30 WO disclosed
US-20160139143-A1 DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY VENTANA MEDICAL SYSTEMS, INC. 2016-05-19 US disclosed
US-9291597-B2 Detecting targets using mass tags and mass spectrometry VENTANA MEDICAL SYSTEMS, INC. (US) 2016-03-22 US disclosed
US-8946302-B2 Selective sigma-1 receptor ligands WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-02-03 US disclosed
US-8946302-B2 Selective sigma-1 receptor ligands WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-02-03 US disclosed
EP-0908186-A2 Method for treating pain ELI LILLY AND COMPANY (US) 1999-04-14 EP disclosed
EP-0908454-A2 Oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents ELI LILLY AND COMPANY (US) 1999-04-14 EP disclosed
EP-0908180-A2 Use of phenyl oxazole or phenyl thiazole derivatives for treating pain ELI LILLY AND COMPANY (US) 1999-04-14 EP disclosed
EP-0906755-A2 Use of phenyl oxazole or phenyl thiazole derivatives for treating neuropathic pain ELI LILLY AND COMPANY (US) 1999-04-07 EP disclosed
WO-1999009979-A1 METHOD FOR TREATING NEUROPATHIC PAIN ELI LILLY AND COMPANY (US) 1999-03-04 WO disclosed
WO-1999009829-A1 METHOD FOR TREATING PAIN ELI LILLY AND COMPANY (US) 1999-03-04 WO disclosed
WO-1999009980-A1 METHOD FOR TREATING PAIN ELI LILLY AND COMPANY (US) 1999-03-04 WO disclosed
WO-1998015274-A1 NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS ELI LILLY AND COMPANY (US) 1998-04-16 WO disclosed
WO-1990002829-A1 ELECTROPOLYMER COATED MICROELECTRODES WOLLONGONG UNIADVICE LIMITED (AU) 1990-03-22 WO disclosed
WO-1990002829-A1 ELECTROPOLYMER COATED MICROELECTRODES WOLLONGONG UNIADVICE LIMITED (AU) 1990-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147383-A1 COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN IKZF2, RPL6, HNRNPR TMEM97 2408/4885SIGMAR1 2876/4885KDM4E 2957/4885
US-11548870-B2 Compounds useful as inhibitors of helios protein IKZF2, RPL6, HNRNPR TMEM97 2408/4885SIGMAR1 2876/4885KDM4E 2957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.